1Valenta R, Vrtala S, Focke Tejkl M, et al. Genetically engineered and synthetic allergen derivatives: candi- dates for vaccination against type I allergy [J]. Biol Chem, 1999, 380(7-8): 815-824.
2Ohashi Y, Nakai Y, Tanaka A, et al. Risk factors for adverse systemic reactions occurring during im- munotherapy with standardized dermatophagoides fari- nae extracts[J]. Acta Otolaryngol, 1998, 538(Suppl): 113- 117.
5Bousquet J, Van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma[J]. J Allergy Clin Immunol, 2001, 108 (5 Suppl): 147- 334.
3Wilson DR, Nouri-Aria KT, Walker SM, et al. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol, 2001,107 (6) : 971-976.
4Gabrielsson S, Soderlund A, Paulie S, et al. Specific immunotherapy prevents increased levels of allergen-specefec IL-4 and IL-13 producing cells during pollen season. Allergy, 2001,56(4) : 293-300.
5Erel F, Kataayvaz M, Caliskaner AZ, et al. Effects of allergen immunotherapy on the nasal mucosa in patients with allergic rhinitis. J Invesrig Allergol Clin Immunol, 2000, 10( 1): 14-19.
6Andre C, Vatrinet C, Galvain S, et al. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol, 2000, 121(2) : 229-234.
7Di Rienzo V, Pagani A, Parmiani S, et al. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy, 1999, 54(10) : 1110-1113.
8Motta G, Passali D, De Vincentiis I. et al. A muhicentre trial of specific local nard immunotherapy. Laryngoscope 2000, 110(1) : 132-139.
9Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med, 1999, 341 ( 7 ) : 468-475.
10Durham SR, Varney VA, Gaga M, et al. Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy,1999, 29(11) : 1490-1496.
